Heart failure drug study halted early – only 4 patients enrolled
NCT ID NCT06581159
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 27 times
Summary
This early-stage study tested a new drug called HS135 in obese patients who have both heart failure with preserved pumping ability and high blood pressure in the lungs. The goal was to check the drug's safety and how the body processes it. Only 4 people took part before the study was stopped early.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY HYPERTENSION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Site-104
Phoenix, Arizona, 85016, United States
-
Site-105
Kansas City, Missouri, 64111, United States
Conditions
Explore the condition pages connected to this study.